This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
BackgroundEmerging genetic and observational evidence indicates that remnant cholesterol (RC) is a significant residual risk factor for cardiovasculardiseases. However, there is a relative paucity of evidence exploring the correlation among RC, lipid ratios, and atherosclerotic lesion severity.
February 1, 2024 — As cardiologists, heart disease patients and the organizations that serve them across the country embark on American Heart Month, DAIC has compiled a snapshot of significant cardiovasculardisease (CVD) and stroke statistics, along with a review of the atherosclerosis drug market. per 1,000* - 122.4
Atherosclerotic cardiovasculardisease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,2 ASCVD causes or contributes to conditions that include coronary artery disease (CAD), cerebrovascular disease, and peripheral vascular disease (inclusive of aortic aneurysm).3
Clinicians currently use two separate risk models to assess patients’ chances of having heart attacks , strokes , and other major cardiovascular events. Clinicians currently use two separate risk models to assess patients’ chances of having heart attacks , strokes , and other major cardiovascular events.
Coronary artery disease is caused by the retention of a cholesterol particle in the artery wall. But if a retained cholesterol particle is the spark. Insulin resistance and diabetes may not ‘ cause ’ coronary artery disease, but they are huge accelerants. This is the spark that sets the fire.
BackgroundAortic stenosis has pathophysiological similarities with atherosclerosis, including the deposition of cholesterol‐containing lipoproteins. The resulting cholesterol crystals activate the NLRP3 (NOD‐like receptor protein 3) inflammasome, leading to inflammation and cardiovasculardiseases. mg/dL versus 97.9±37.6
Insulin resistance is a major risk factor for the leading causes of death, the leading one being cardiovasculardisease. Understanding where you sit on this continuum is a key part of defining your future risk of heart disease but also dementia, and many cancers. Low HDL Cholesterol. But What Causes Insulin Resistance?
For many disease areas, nearly a half of drugs are approved by the U.S. For cardiovasculardisease, only low-density lipoprotein cholesterol and blood pressure are approved as surrogates for cardiovasculardisease. Food & Drug Administration based on beneficial effects on surrogate endpoints.
This study sought to evaluate the prevalence of cardiovascular risk factors, overt cardiovasculardisease and cardiac imaging abnormalities using cardiac magnetic resonance (CMR), in participants with normal LVEF on completion of trastuzumab±anthracycline therapy at least 5 years previously. years (range 5.9–10.8
CLEAR Trial of Bempedoic Acid Bempedoic acid is an ATP citrate lyase inhibitor, acting upstream of HMGCoA reductase targeted by statins, and reduces LDL cholesterol levels. CLEAR trial had patients for both primary and secondary prevention of cardiovasculardisease. Median follow up was for 40.6 There was 29.2
However Most people do not appreciate that being a carrier of APOE4 significantly increases the risk of cardiovasculardisease also. APO E is also centrally involved in cholesterol metabolism. APO E is also centrally involved in cholesterol metabolism. i.e. LDL-Cholesterol/APOB goes down. Here’s how.
I do apologise for being direct, but this issue is one of the most frequent barriers I encounter to initiating cholesterol-lowering therapy. At the exact same time, cholesterol concentrations are also at their lowest. At the exact same time, cholesterol concentrations are also at their lowest. Let’s break this down.
BACKGROUND:The relationship between marijuana use and cardiovascular health remains uncertain, with several observational studies suggesting a potential association with increased adverse atherosclerotic cardiovasculardisease (ASCVD) outcomes. mg/dL,P=0.53), total cholesterol (191.2 female; 13% non-Hispanic Black), 26.6%
BackgroundPatients with nonalcoholic fatty liver disease are at increased risk to develop atherosclerotic cardiovasculardiseases. The expression of GPBAR1 in the human endothelium correlated with the expression of inflammatory biomarkers. Journal of the American Heart Association, Volume 12, Issue 23 , December 5, 2023.
It is currently unknown if these associations are confounded by pleiotropic effects of the instrumental variables (IV) on cardiovasculardisease (CVD) risk factors, such as low-density lipoprotein cholesterol (LDL), diastolic blood pressure (DBP), and body mass index (BMI).
In my experience, some patients present later in life with a significantly elevated Lp(a) but have no evidence of coronary artery disease. They have the biomarker of risk but no evidence of the disease , even later in life when you would expect them to have it. This is the case with an elevated Lp(a). Atherosclerosis.
I, Dr Malcolm Kendrick, with or without other co-conspirators, would be accused of spreading misinformation about cholesterol and statins. The hypothesis that a raised cholesterol level causes heart disease [atherosclerotic cardiovasculardisease (ASCVD)] is possibly the single most powerful idea in medicine.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content